TICKERNERD
Menu
DRIODRIOHealthcare · Health Information Services

DRIO Stock Forecast: DarioHealth Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$2.97
−1.00% on the day

The 6 Wall Street analysts covering DarioHealth Corp. hold a median 12-month price target of $10 — +236.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 4 Nov 2026 — in the lower half.

Market cap
$29.0M
Ticker Nerd rank
49/ 100
Median analyst target
$10
Analysts covering
6
Revenue$5.2M−3.6% y/y
Operating income−$6.5M
Net income−$7.9M
Free cash flow−$6.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.9%
1M
−54.0%
YTD
−73.9%
1Y
−78.0%
From 52W high
−78.8%
From 52W low
0.0%
$3
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DRIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DarioHealth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
49/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Accruals
84
Growth
75
Volatility
69
Revisions
60
Quality
46
Value
26
Issuance
15
Momentum
7

Size (85): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DRIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26DRIOHigh $28Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $6Median $10High $28

The green dot is the last close — the median target sits +236.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Oct 2026BTIGInitiatesBuy$6.00
19 Aug 2026Alliance Global PartnersInitiatesBuy$12
19 Aug 2026Alliance Global PartnersInitiatesBuy—
12 Aug 2026TD CowenMaintainsHold$11 → $8.00
12 Aug 2026TD CowenMaintainsHold—
14 May 2026StifelReiteratesBuy$10
14 May 2026StifelReiteratesBuy—
13 May 2026TD CowenMaintainsHold$11
13 May 2026TD CowenMaintainsHold—
20 Mar 2026StifelMaintainsBuy—
19 May 2025Litchfield HillsInitiatesBuy—
11 Mar 2025StifelMaintainsBuy—
1 Apr 2024StifelMaintainsBuy—
11 Aug 2023Alliance Global PartnersMaintainsBuy—
25 July 2023StifelMaintainsBuy—
12 May 2023Craig-HallumMaintainsBuy—
16 Nov 2022Alliance Global PartnersMaintainsBuy—
18 Aug 2022Aegis CapitalMaintainsBuy—
16 Aug 2022Cowen & Co.MaintainsOutperform—
16 May 2022Aegis CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DRIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DRIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, DarioHealth Corp. returned −78.0% against +14.8% for the S&P 500, dividends included.

DRIO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26DRIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DRIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

DarioHealth Corp. (DRIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 80% of US stocks

Price / sales
1.4×

Cheaper than 60% of US stocks

Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
−1.6×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−3.6%

Higher than 22% of US stocks

Earnings growth (YoY)
−3.6%

Higher than 33% of US stocks

Gross margin
61.7%

Higher than 75% of US stocks

Operating margin
−125.2%

Higher than 13% of US stocks

Net margin
−169.9%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−59.9%

Higher than 19% of US stocks

Return on assets
−19.4%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DarioHealth Corp. (DRIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DarioHealth Corp. has a market value of $29.0M and an enterprise value of $47.9M.

  • Revenue in the twelve months to 30 June 2026: $21.0M. The latest quarter shrank 3.6% year on year.

  • Net income over the same four quarters: −$35.7M, a −169.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$25.5M.

  • Shares outstanding: 7.3M.

  • Trailing P/E: −0.3×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • DarioHealth Corp. employs 160 people — $131K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

DRIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
DRIODarioHealth Corp.$29.0M49
ONMDOneMedNet Corp.$27.3M10
BEATHeartBeam, Inc.$23.9M26
CCLDCareCloud, Inc.$76.5M77
BFRGBullFrog AI Holdings, Inc.$9.7M47
LFMDLifeMD, Inc.$117.9M45
HCATHealth Catalyst, Inc.$119.7M57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DarioHealth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DRIO news & analysis

Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

PRNewsWire · 4 Nov 2026positive

DarioHealth appointed John R. Palumbo Chairman of the Board, effective November 3, 2026. The company said he will join its third-quarter 2026 earnings call to discuss the Board’s view on the convergence of consumer- and payer-led healthcare and chronic care management.

Why it matters — The leadership appointment and planned call will give DRIO watchers insight into the Board’s perspective on the company’s stated healthcare focus.

DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026

PRNewsWire · 2 Nov 2026neutral

DarioHealth announced it will release its financial results for the third quarter ended September 30, 2026, on November 12, 2026. The company will host a conference call and webcast at 8:30 a.m. Eastern Time.

Why it matters — DRIO watchers can note the scheduled date and time for the company’s quarterly results and related call.

This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga · 27 Oct 2026neutral

Benzinga reports that Wall Street analysts changed their outlooks on several companies, highlighting five initiations for Tuesday. The provided excerpt does not identify DarioHealth or describe an analyst action for DRIO.

Why it matters — The item provides no specific analyst rating or outlook for DRIO, so it offers no direct company-specific update for DRIO watchers.

Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program

PRNewsWire · 26 Oct 2026positive

DarioHealth said a regional grocery retailer expanded its contract to add Dario Women, its digital health program for perimenopause and menopause support. The program is expected to be offered to eligible insured employees starting in January 2027.

Why it matters — The contract expansion adds a women's health offering to Dario's existing client relationship and could increase its annual recurring revenue base.

DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

PRNewsWire · 6 Oct 2026positive

DarioHealth reported that an independent Aon review found evidence supporting an estimated 2.5%–7.2% annual reduction in total healthcare costs across a covered population. The review also cited a component study showing $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes than matched non-users.

Why it matters — The analysis offers evidence of potential cost savings that may support the value proposition of DarioHealth’s platform to payers and other customers.

FAQ

Frequently asked questions about DRIO stock

What is the DRIO stock price forecast for 2026-2027?

The 6 Wall Street analysts covering DarioHealth Corp. have a median 12-month price target of $10, with estimates ranging from $6 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRIO stock a buy right now?

Of the 6 analysts covering DarioHealth Corp., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DarioHealth Corp. 49 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRIO?

As at 4 Nov 2026, DarioHealth Corp. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will DRIO stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +236.7% from the last close, and Ticker Nerd's factor model ranks DarioHealth Corp. 49 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRIO stock forecast for 2030?

No analyst covering DarioHealth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $28 over the next 12 months.

How has DRIO stock performed over the past year?

DarioHealth Corp. returned -78.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DarioHealth Corp. do?

DarioHealth Corp. is a digital health company that provides connected, data-driven solutions for chronic condition management.

What is the latest news on DRIO?

The most recent item we track (PRNewsWire, 4 Nov 2026): "Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care". DarioHealth appointed John R. Palumbo Chairman of the Board, effective November 3, 2026. The company said he will join its third-quarter 2026 earnings call to discuss the Board’s view on the convergence of consumer- and payer-led healthcare and chronic care management.

Company

About DarioHealth Corp.

DarioHealth Corp. is a digital health company that provides connected, data-driven solutions for chronic condition management. DarioHealth focuses on supporting people living with diabetes, hypertension, weight management needs, musculoskeletal pain, and behavioral health conditions through its integrated digital therapeutics platform. Its offerings combine mobile software, connected monitoring devices, personalized interventions, and live coaching to deliver ongoing support between clinical visits. The company’s product suite includes solutions for metabolic health, musculoskeletal care, behavioral health, and broader chronic condition management, serving health plans, employers, providers, and consumers across multiple markets. DarioHealth Corp. plays a role in the healthcare technology sector by helping make chronic care more accessible, personalized, and scalable through software-based care delivery and remote monitoring tools.

CEO Mr. Erez Raphael · 160 employees · United States · https://www.dariohealth.com